

Company Announcement

15 November 2010

Novo Nordisk A/S – Share repurchase programme

On 27 October 2010 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.4 billion in the period from 27 October 2010 to 23 December 2010.

Since the announcement as of 8 November 2010, the following transactions have been made under the programme:

| | Number of shares | Average purchase price | Transaction value, DKK |
|--|-------------------------|-------------------------------|-------------------------------|
| Accumulated, last announcement | 485,000 | | 268,521,512 |
| 8 November 2010 | 50,000 | 555.2200 | 27,761,000 |
| 9 November 2010 | 50,000 | 559.0200 | 27,951,000 |
| 10 November 2010 | 50,000 | 566.6700 | 28,333,500 |
| 11 November 2010 | 40,000 | 565.7900 | 22,631,600 |
| 12 November 2010 | 40,000 | 565.9900 | 22,639,600 |
| Accumulated under the programme | 715,000 | | 397,838,212 |

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 42,050 B shares in the period from 8 November 2010 to 11 November 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 27,290,155 treasury shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,890 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Anne Margrethe Hauge
Tel: (+45) 4442 3450
amhg@novonordisk.com

Investors:

Klaus Bülow Davidsen
Tel: (+45) 4442 3176
klda@novonordisk.com

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
krop@novonordisk.com

Jannick Lindegaard
Tel: (+45) 4442 4765
jlis@novonordisk.com

In North America:

Lori Moore
Tel: (+1) 609 919 7991
lrmo@novonordisk.com

In North America:

Hans Rommer
Tel: (+1) 609 919 7937
hrrmm@novonordisk.com